Found: 18
Select item for more details and to access through your institution.
The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis.
- Published in:
- Dermatologic Therapy, 2024, v. 2024, p. 1, doi. 10.1155/2024/4115539
- By:
- Publication type:
- Article
Real‐world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single‐center retrospective study.
- Published in:
- Journal of Dermatology, 2024, v. 51, n. 5, p. 649, doi. 10.1111/1346-8138.17186
- By:
- Publication type:
- Article
Dietary habits in adult Japanese patients with vitiligo.
- Published in:
- Journal of Dermatology, 2024, v. 51, n. 4, p. 491, doi. 10.1111/1346-8138.17163
- By:
- Publication type:
- Article
Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 12, p. 1576, doi. 10.1111/1346-8138.16950
- By:
- Publication type:
- Article
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 10, p. 1301, doi. 10.1111/1346-8138.16879
- By:
- Publication type:
- Article
Two cases of generalized pustular psoriasis successfully treated with bimekizumab.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 10, p. e357, doi. 10.1111/1346-8138.16866
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 7, p. 869, doi. 10.1111/1346-8138.16763
- By:
- Publication type:
- Article
The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan.
- Published in:
- Journal of Dermatology, 2022, v. 49, n. 11, p. 1158, doi. 10.1111/1346-8138.16549
- By:
- Publication type:
- Article
Case of subcorneal pustular dermatosis during carfilzomib treatment for immunoglobulin G κ multiple myeloma.
- Published in:
- Journal of Dermatology, 2021, v. 48, n. 1, p. e37, doi. 10.1111/1346-8138.15622
- By:
- Publication type:
- Article
The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 6, p. 2201, doi. 10.3390/jcm12062201
- By:
- Publication type:
- Article
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 5, p. 1934, doi. 10.3390/jcm12051934
- By:
- Publication type:
- Article
Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 3, p. 974, doi. 10.3390/jcm12030974
- By:
- Publication type:
- Article
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 4, p. 261, doi. 10.1007/s40261-024-01352-4
- By:
- Publication type:
- Article
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 3201, doi. 10.2147/CCID.S439053
- By:
- Publication type:
- Article
A Case of Darier's Disease with a Novel Missense Mutation in ATP2A2 Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound Ointment.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Dietary Habits in Japanese Patients with Alopecia Areata.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2021, v. 14, p. 1579, doi. 10.2147/CCID.S335440
- By:
- Publication type:
- Article
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1365544
- By:
- Publication type:
- Article
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 519, doi. 10.3390/ph17040519
- By:
- Publication type:
- Article